Angiogenesis inhibiting agents are currently integral component of anticancer therapy. However, tumors, initially responsive to anti-angiogenic drugs or vascular targeting agents, can acquire resistance. The limited clinical efficacy might result from the heterogeneous nature of tumors or alternatively from the unique phenotype of tumor vascular cells, widely diverse from so-called 'normal' endothelium. Hence, defining the molecular mechanisms driving this diversity might provide a rational basis to design combinatory therapies that should be more effective in avoiding resistance. Herein, we demonstrated that tumor-derived endothelial cells (TECs) isolated from breast and kidney carcinomas retained an endothelial phenotype, but outspread independently of growth factors. Applying small interfering RNA approach, we demonstrated that interleukin (IL)-3, but not vascular endothelial growth factor, released by TECs, supports their autocrine growth and promotes in vivo vessel formation and tumor angiogenesis. Meanwhile, we found that the expression of the membrane-bound kit ligand (mbKitL) depends on IL-3, and it is crucial for adhesion of endothelial progenitor cells (EPCs) and inflammatory cells to TECs. These events required Akt activation. Finally, the finding that depletion of the mbKitL prevented EPC and inflammatory cell trafficking into vascular microenvironment, indicates that, as in bone marrow, the mbKitL can act as a membrane/adhesion molecule for c-Kit-expressing cells. These data provide evidences that an IL-3 autocrine loop can drive a tumor endothelial switch and that targeting IL-3 might confer a significant therapeutic advantage to hamper tumor angiogenesis.
Introduction
For a tumor to develop as a highly malignant and deadly phenotype, it must recruit and sustain its own blood supply, a process known as tumor angiogenesis (Folkman, 2007) . Tumor blood vessels provide nutrition and oxygen in response to demand of proliferating tumor cells and act as gatekeepers for tumor-cell escape to enter into the circulation, thus favoring metastasis (Folkman, 2007; Shchors and Evan, 2007; Kerbel, 2008) . Actually, it is well established that, in term of morphology, tumor-derived endothelial cells (TECs) possess a distinct and unique phenotype compared with normal endothelial cells (NECs) (Baluk et al., 2003) . Also, evidences indicate that there are differences at the molecular and functional levels. Unlike NECs in normal quiescent endothelium, TECs have a rapid turnover rate and therefore have been termed 'activated'. The 'activated' phenotype of TECs (Folkman, 2007) has been related to the expression of embryonic genes (St Croix et al., 2000) as well as genes regulating vessel growth, including the interleukin (IL)-3 gene (Bussolati et al., 2003) . The inflammatory cytokine IL-3, released into tumor microenvironment (Dentelli et al., 2004) , besides promoting survival and proliferation of mature endothelial cells (Dentelli et al., 1999) , also acts as an endothelial differentiation factor for hematopoieticderived endothelial progenitor cells (EPCs) (Zeoli et al., 2008) . Indeed, tumor neovasculature is widely believed to have two distinct extra-tumoral origins. The first, arising through a process termed 'angiogenesis', originates from the sprouting of new capillaries from pre-existing vessels in geographical proximity to the tumor. The second, known as 'vasculogenesis', arises from the recruitment into the tumor bed of bone marrow-derived hematopoietic/EPCs and their subsequent differentiation into endothelial cells (Tonini et al., 2003; Folkman, 2007; Verfaillie, 2008) .
Hematopoietic and endothelial cells as well as EPCs express c-Kit, the receptor for c-Kit ligand (KitL) (Flanagan et al., 1991) . The KitL is expressed as both membrane-bound (mbKitL) and soluble (sKitL) form (Huang et al., 1992; Matsuda et al., 1993) . In bone marrow, the mbKitL expressed by stromal cells, acts as membrane-bound adhesion/survival-promoting molecule for hematopoietic cells (Flanagan et al., 1991) . Hematopoietic cells have composite functions in tumor development (De Palma and Naldini, 2006; Takakura, 2006) . In particular, myeloid-lineage cells usually referred as inflammatory cells, abundantly infiltrate human tumors (Takakura, 2006) . Although these cells can destroy tumors, several evidences indicate that they can also promote tumorigenesis by promoting the development of tumor-associated blood vessels (Mantovani et al., 2008) . In particular, it has been shown that hematopoietic cells are located around newly formed blood vessels and tumor formation is enhanced when hematopoietic cells migrated into the tumor. These findings indicate that recruitment of hematopoietic cells may precede and dictate the induction of angiogenesis in tumors (Lin et al., 2006) . It is currently accepted that inflammatory cell and EPC trafficking into tumor microenvironment relies on a constitutive expression of adhesion molecules by TECs (Ribatti et al., 2007) . As in sites of inflammation, a coordinated sequence of adhesive and signalling events, including selectin-mediated rolling, leukocyte activation by chemokines, integrin-mediated firm adhesion and diapedesis controls this process (Vajkoczy et al., 2003; Biancone et al., 2004) . It has been shown that, along with the canonical adhesion/recruiting molecules, the mbKitL expressed by proliferating endothelial cells contributes to c-Kit-positive cell trafficking into neoangiogenetic sites (Dentelli et al., 2007) . Thus, the spliced variant of the cKit ligand might act as an adhesion/recruiting molecule for c-Kit-expressing cells in tumor as well.
As a result of their critical role for tumor growth, tumor blood vessels are recognized as potential antitumoral drug targets. Thus, in this study we attempted to dissect the molecular mechanisms driving a tumor endothelial switch in order to provide a rational basis to interfere with vascular growth in cancer.
Results

TEC characterization and functional behavior
TECs widely differ in terms of surface markers from their normal counterpart (Baluk et al., 2003; van Beijnum et al., 2009) . Thus, TECs, isolated from renal clear cell carcinomas and breast carcinomas by CD105-positive immunomagnetic sorting (Bussolati et al., 2003; Grange et al., 2006) , were first analyzed for endothelial cell surface markers by cytofluorimetric analysis. As reported in Figure 1a , we found that renal TECs (rTECs) were positive for the expression of several endothelial cell markers, such as CD105, CD146 (c) Cell migration assay was performed in Boyden's chambers, as described in Materials and methods section. NECs untreated, or treated with IL-3 (20 ng/ml) in migration assay, were used as control (*Po0.05, NECs þ IL-3, rTECs and mTECs versus NECs). All data reported are representative of three independent experiments performed in triplicate.
IL-3 drives tumor endothelial phenotype P Dentelli et al Fold expression of IL-3 or VEGF, normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was representative of three independent experiments performed in triplicate. Gibbon MLA cell line or IL-3-treated NECs were used as positive controls ( þ ) for IL-3 and VEGF mRNA expression, respectively (*Po0.05, rTECs and mTECs versus NECs). The release of IL-3 was also analyzed by western blot on 40 Â concentrated TEC-culture medium (right panel). Human recombinant IL-3 (hrIL-3, 2 ng/ml) was used as positive control. (b) The expression of the IL-3 receptor beta common subunit (IL-3Rbc) was evaluated by western blot or by cytofluorimetric analysis on NECs, rTECs or mTECs. For western blot analysis cell extracts were immunoprecipitated (IP) with an anti-IL-3Rbc-Ab and subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). (c) Cell proliferation (upper panel) and cell migration (lower panel) assays were performed with rTECs or mTECs, pre-treated or not with a specific IL-3-neutralizing Ab (40 mg/ml) or endogenously depleted of IL-3 (siRNA IL-3) (*Po0.05, anti-IL-3 Ab-treated or IL-3-depleted rTECs and mTECs versus basal rTECs and mTECs). Cell-cycle data are reported as the percentage ± s.d. of cells in each cell-cycle phase. All data reported are representative of three independent experiments performed in triplicate. Figure 1a) . A similar surface expression profile was detected in mammary-derived TECs (mTECs) (data not shown). As extensively documented, TECs also differ from their normal counterpart for a rapid turnover rate in absence of growth factors (Bussolati et al., 2003; Grange et al., 2006) . Indeed, monitoring rTEC and mTEC growth at low serum concentration (2%) for different time intervals (24, 48 and 72 h), an increase in cells in the S phase ( Figure 1b , upper panel) could be detected and this increased proliferative rate (Figure 1b , lower panel) was maintained for several passages (12 passages, data not shown). Moreover, we found that chemotactic stimuli are not required for rTECs and mTECs motogenic activity ( Figure 1c ).
IL-3 is crucial for TEC outspread both in vitro and in vivo To define the molecular mechanisms regulating TEC pro-angiogenic capability the autocrine secretion of angiogenic growth factors was investigated. In line with data obtained by TEC gene expression profile (Bussolati et al., 2003) (Figure 2a , left panel) we demonstrated that both rTECs and mTECs were able to synthesize IL-3 but not VEGF. The release of IL-3 was verified by western blot analysis ( Figure 2a , right panel) and by enzyme-linked immunosorbent assay (Supplementary Figure S1A ) on conditioned media recovered from both rTECs and mTECs. In addition, both western blot and fluorescence-activated cell sorting analysis revealed that either rTECs or mTECs expressed the IL-3 receptor beta common subunit (IL-3bc) (Figure 2b ), sustaining the possibility that an autocrine loop may support their intrinsic pro-angiogenic behavior. Therefore, functional studies were performed on rTECs and mTECs subjected to small interfering RNA (siRNA) technology. As reported in Figure 2c both rTECs and mTECs endogenously depleted of IL-3 (Supplementary Figure  S2A) , showed an impaired motogenic activity and failed to proliferate ( Figure 2c and Supplementary Figure  S1B ). Similar results were obtained with rTECs and mTECs treated with a specific IL-3-neutralizing antibody (Ab) (Figure 2c and Supplementary Figure S1B ). To verify these results in vitro and in vivo angiogenesis assays were performed. Data reported in Supplementary Figure S3 and Figure 3a , demonstrating that IL-3-depleted TECs were unable to form tube-like structures in vitro (Supplementary Figure S3 ) or to organize themself into vascular structures in vivo (Figure 3a ), add further supports to the crucial role played by IL-3 in controlling these processes. Akt has been reported to be crucial for TEC survival . Thus, TECs treated with a specific IL-3-neutralizing Ab or endogenously depleted of IL-3 (Supplementary Figure S2A) were analyzed for Akt activation. As shown in Figure 3b , we failed to detect Akt activation in both experimental conditions. Moreover, the finding that TECs depleted of Akt (Supplementary Figure S2B ) or subjected to LY294002 treatment failed to enter into the cell-cycle and to proliferate ( Figure 3c and Supplementary Figure S4A ) suggests that Akt, as IL-3 blockade, could restore a quiescent phenotype. Indeed, as the result of Akt depletion TECs failed to migrate and to form vessels in vivo (Figure 3a and Supplementary Figure S4B ).
The expression of the mbKitL is under the control of IL-3 and contributes to EPC and inflammatory cell trafficking IL-3 acts as a pro-inflammatory cytokine and drives proliferation, migration and functional activation of endothelial cells (Brizzi et al., 1993; Dentelli et al., 1999) . Thus, the ability of IL-3 to direct the expression of adhesion molecules on TECs was first evaluated. By applying siRNA technology or neutralizing Ab, we herein demonstrate that IL-3, released by TECs, is crucial for inter-cellular adhesion molecule-1, E-selectin and the mbKitL expression ( Figure 4a ). Moreover, the finding that a reduced expression of inter-cellular adhesion molecule-1, E-selectin and the mbKitL was detected after Akt blockade or depletion (Supplementary Figure S4C ) confirms the crucial role of Akt in controlling IL-3-mediated biological events. As in the bone marrow niches (Flanagan et al., 1991) , the mbKitL on proliferating endothelial cells acts as an adhesion molecule for EPCs in sites of neovascularization (Dentelli et al., 2007) . To assess whether the constitutive expression of the mbKitL by TECs might also regulate inflammatory cell and EPC trafficking into angiogenic sites, an adhesion assay was performed in different experimental conditions. The results reported in Figure 4b demonstrated that both inflammatory cells and EPCs expressing c-Kit (Figure 4c ) adhered to TECs and that adhesion was prevented ( Figure 4b ) when TECs were silenced for IL-3 or for the mbKitL (Supplementary Figure S2B) . Moreover, in line with the role of Akt in mediating cell adhesion (Dentelli et al., 2007) , we found that Akt is also crucial for adhesion of EPCs and inflammatory cells to TECs (Figure 4b ). To validate the contribution of the mbKitL in regulating EPC and inflammatory cell homing into active sites of angiogenesis, in vivo experiments were performed. To this end, rTECs were added to Matrigel in presence or in absence of an anti-mbKitL-neutralizing Ab and implanted subcutaneously into severe combined immunodeficient (SCID) mice. After 7 days, Matrigel plugs were recovered and analyzed for the presence of inflammatory cells. Alternatively, 5 days after TEC implantation, EPCs were injected intravenously through the tail vein, and 2 days later Matrigel plugs were recovered and analyzed. As shown in Figure 5 , TECs formed functional vessels and EPCs (about 5% of the total CD31-positive cells) could be luminally incorporated into the nascent vessels. Moreover, in plugs containing the anti-mbKitL Ab ( Figure 5 ) either the number of EPCs luminally inserted and the number of CD68 þ cells located around the newly formed blood vessels IL-3 drives tumor endothelial phenotype P Dentelli et al were reduced, indicating that the mbKitL expressed by TECs might act as an homing signature for both EPCs and inflammatory cells. Similar results were obtained with mTECs (data not reported). Finally, we found that functional inactivation of the mbKitL impairs vessel formation as well ( Figure 5 ).
IL-3 targeting impairs tumor vessel formation and tumor growth
As tumor vasculature is crucial for growth and invasion of tumor cells (Shchors and Evan, 2007) , we investigated the biological relevance of IL-3 in controlling neovessel formation in tumor. To this end, primary renal IL-3 drives tumor endothelial phenotype P Dentelli et al carcinoma cells were injected in SCID mice in presence or in absence of a specific IL-3-neutralizing Ab. Tumor growth was assessed at the indicated days ( Figure 6a ) and after 4-5 weeks a visible tumoral mass had developed in untreated mice compared with mice injected with the IL-3-neutralizing Ab (430 ± 30 mm 3 untreated mice versus 110±20 mm 3 anti-IL-3 Abtreated mice). These tumors were recovered and analyzed for vascular density. As shown in Figure 6b , a reduced vascular density was detected in tumors injected with the IL-3-neutralizing Ab, indicating that targeting IL-3 has an effect on tumor vasculature as well. Moreover, as indicated by the tumoral volume, interfering with IL-3 also impaired tumor expansion.
Discussion
Blood vessels in tumor tissue are major components of the tumor microenvironment. These vessels are newly formed from pre-existing host vessels stimulated by proangiogenic factors expressed in tumor cells. Hence, tumor cells establish a specific stromal microenvironment fostering tumor growth, in which angiogenesis is IL-3 drives tumor endothelial phenotype P Dentelli et al involved (Folkman, 2007; Shchors and Evan, 2007; Kerbel, 2008) . Tumor-associated angiogenesis is continually sustained by complicated cytokine networks, namely pro-angiogenic factor-mediated paracrine and autocrine interactions among tumor cells and stromal cells (including ECs, non-endothelial mesenchymal cells and inflammatory cells) (Butler et al., 2010) . Inflammatory cells, including T-lymphocytes, act as regulatory cells releasing a vast array of soluble proangiogenic mediators that, on turn, can directly or indirectly modulate tumor angiogenesis. Actually, IL-3, released by a subset of tumor-infiltrating CD25/CD4/ CD5 þ T cells in breast and ovarian cancer tissues, has been reported to enhance tumor angiogenesis (Dentelli et al., 2004) . We herein demonstrate that in vivo human TECs have an intrinsic pro-angiogenic capability, property that is independent of tumor microenvironment and is driven by their autocrine release of IL-3. Moreover, by applying siRNA technology, we were able to demonstrate that signals emanated by IL-3 binding to its receptors are crucial for TEC proliferation and migration in vitro and for in vivo vessel formation as well. Blood vessels supplying tumors are considered unique as they differ from their normal counterparts with respect to morphology, pathophysiology, gene expression profile and outgrowth in the absence of growth factors (St Croix et al., 2000; Baluk et al., 2003) . Considerable evidences have currently emerged sustaining the key role of Akt in driving TEC proangiogenic phenotype (Bussolati et al., , 2010 . Our results showing that IL-3, via Akt, drives TECindependent growth and that blockade of IL-3 or its signalling molecule Akt in vivo prevents both tumor angiogenesis and growth, provide a mechanistic ratio- Figure 5 The expression of the mbKitL induced by IL-3 contributes to EPC and inflammatory cell trafficking into active sites of angiogenesis. SCID mice were injected subcutaneously (s.c.) with Matrigel containing 2 Â 10 6 TECs in presence or in absence of antimbKitL Ab. Matrigel plugs were recovered 7 days after implantation and analyzed by immunohistochemistry using an anti-CD68 Ab to detect inflammatory cells (upper panels) or an anti-fluorescein/Oregon Green polyclonal Ab to detect EPCs (lower panels). For details see Materials and methods section. In the upper panels, red arrows indicated CD68 þ inflammatory cells located around the neoformed vessels. In the lower panels, red arrows indicated brown labelled EPCs, incorporated into TEC neoformed vessels. Black arrows indicated vessels formed by TECs. Quantification of vessel density was evaluated by human CD31 staining. Only vessels possessing a patent lumen containing red blood cells were considered for this study. Histograms represent the number (mean±s.d.) of: (i) vessels per field; (ii) labelled EPCs per vessel; (iii) inflammatory cells per field, in different experimental conditions ( Â 20 magnification). Scale bars indicate 50 mm (*Po0.05, experimental versus control values). Ten randomly selected fields from six different sections for each individual experimental group were analyzed. IL-3 drives tumor endothelial phenotype P Dentelli et al nale for targeting IL-3 to achieve additional antitumoral effects. Although tumor cells were first thought to drive the cellular events underpinning tumor angiogenesis and growth, considerable evidence has now emerged for the central role of tumor-infiltrating myeloid cells in this phenomenon (De Palma and Naldini, 2006; Takakura, 2006) . These cells are actively recruited into the tumor microenvironment from the bloodstream. Inflammatory cell trafficking in vivo is regulated by chemokines and by members of the integrin, immunoglobulin superfamily and selectin adhesion molecule families (Luster et al., 2005; Weber and Koenen, 2006) . IL-3, on NECs, acts as a pro-inflammatory molecule able to induce the expression of adhesion molecules regulating inflammatory cell trafficking into sites of inflammation (Brizzi et al., 1993) . The results of this study reveal that IL-3, via Akt, besides acting as prosurvival factor for TECs, also controls the expression of E-selectin, inter-cellular adhesion molecule-1 and the mbKitL as well. Stromal cells in bone marrow specifically express the mbKitL and its expression is required to anchor and maintain hematopoietic stem cells into the quiescent niche (Flanagan et al., 1991) . Similarly, in peripheral active angiogenic sites, the mbKitL acts as an adhesion receptor for circulating cells (Dentelli et al., 2007) , sustaining the possibility that, in TECs as well, the expression of the mbKitL might contribute to the recruitment of c-Kit-expressing cells. Such an event was found crucial for both EPCs and inflammatory cells, as either by targeting IL-3 or the mbKitL, they failed to adhere to TECs.
The discrepancies surrounding the definition of EPCs have made it difficult to identify these elusive cells in vivo, especially in tumors. Bone marrow has been proposed as a depot for circulating EPCs in humans and in mouse tumor models although it is not always clear whether the identified cells are EPCs or hematopoietic cells located close to the blood vessel wall (Yoder and Ingram, 2009) . Moreover, the absolute number of putative bone marrow EPCs is suggested to differ dramatically depending on the tumor site, mouse strain, stage of tumor progression and method of quantification (Nolan et al., 2007; Gao et al., 2009) . For these reasons, EPC designation is currently based on EPC functional features and in particular on their in vivo vasculogenetic capability (Yoder and Ingram, 2009 ). Herein, we provide evidence that EPCs could be luminally incorporated into TEC formed vessels, and that the mbKitL contributes to this event.
A strong correlation exists between tumor-infiltrating inflammatory cell densities and vascular densities in many human tumor types. Additionally, high densities of tumor-infiltrating inflammatory cells are indicative of poor prognoses in many cancers (Nishie et al., 1999; Leek and Harris, 2002) . The tumor-promoting properties of tumor-infiltrating myeloid cells identify these cells as putative targets for anticancer therapies (Sica et al., 2007) . Our results showing that the mbKitL, expressed by TECs, might act as a homing signature for myeloid cells at the angiogenic sites and that its functional inactivation reduces vessel formation suggest that targeting the mbKitL may represent an alternative therapeutic approach to achieve an indirect favorable effect on tumor angiogenesis.
Accomplishment of a tumor to recruit new vasculature or to reorganize the existing surrounding vasculature results in an angiogenic and progressing tumor. Thus, the therapeutic potential of targeting tumor endothelium to induce tumor regression is now widely recognized. However, anti-angiogenic therapies have not fulfilled the initial expectations. Currently, antiangiogenic agents are considered most efficacious when combined with cytotoxic agents and/or therapies targeted toward ablating myeloid cells (Ferrara and Kerbel, 2005; Kerbel, 2008) . Thus, our findings demonstrating that IL-3 may promote tumor angiogenesis and contribute to myeloid cell recruitment provide the mechanistic rational to exploit IL-3 as an alternative target that, in complementary approaches, might confer a significant therapeutic advantage. 
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Materials and methods
Reagents and Abs, western blot analysis, siRNA technology, cell migration and enzyme-linked immunosorbent assay assays were described in details in the online supplemental data.
Cell cultures
Human TECs derived from kidney and breast carcinomas (both cell lines were derived from primary tumors; breast carcinoma cells were derived from a woman 48 years old: T3bG2N0M0, while renal carcinoma cells were derived from a man 55 years old: T1bG2N0M0), kindly provided by Professor Camussi, were isolated and grown as previously described (Bussolati et al., 2003; Grange et al., 2006) . rTECs and mTECs were maintained in endothelial basal medium-2 medium supplemented with 2% of fetal bovine serum until twelfth passage. NECs were isolated from human umbilical veins within 4 h following delivery and cultured as previously described (Dentelli et al., 1999) . To isolate EPCs (Yoder et al., 2007) , peripheral blood mononuclear cells were recovered from blood donors subjects to Ficoll Histopaque 1077 (SigmaAldrich, St Louis, MO, USA) stratification and cultured onto collagen-1-coated dishes for 21 days in endothelial-cell growth medium-2 medium as previously described (Togliatto et al., 2010; Uberti et al., 2010) . peripheral blood mononuclear cells were also subjected to hyper-and iso-osmotic Percoll solutions to isolate monocyte fraction, cultured in presence of granulocyte-macrophage colony-stimulating factor (10 ng/ml) and denoted as inflammatory cells throughout the study. The approval was obtained from SIMT (Servizio Immunoematologia e Medicina Trasfusionale, Torino, Italy) and from the Institutional Review Board of the hospital. Informed consent was provided according to the Declaration of Helsinki. M07e cells (Avanzi et al., 1990) and IL-3 releasing gibbon MLA cell line (Brizzi et al., 2001) were used as positive control for c-Kit or IL-3 expression, respectively. Primary renal carcinoma cells were obtained from an informed patient (cells derived from a man 50 years old: T3bG2N0M0) who underwent clinical surgery. Cell cultures, generated by disaggregating the fresh tumors, were maintained in RPMI supplemented with 5% of fetal bovine serum. In selected experiments rTECs or mTECs were pre-incubated for different time intervals with specific anti-IL-3 or anti-mbKitL-neutralizing Abs (40 mg/ml each) or with a specific Akt inhibitor, Ly294002 (20 mM). Cell viability was evaluated by Trypan blue at the end of each experiment. NEC, rTEC and mTEC proliferative activity was evaluated after 24, 48, 72 and 96 h of culture by a direct cell count (10 fields at Â 20 magnification per sample). Each experiment was performed in triplicate and count was performed by three different operators.
Flow cytometry
To analyze cell-cycle progression, fluorescence-activated cell sorting analysis was performed, as previously described (Defilippi et al., 2005) , on NECs, rTECs or mTECs, cultured for 24-48-72 h with 2% of fetal bovine serum, in presence or in absence of the anti-IL-3-neutralizing Ab or the Akt inhibitor, Ly294002, or alternatively on IL-3-or Akt-depleted cells (analyzed 48 h later). Briefly, after treatment, cells were fixed with 70% ethanol, DNA was stained with propidium iodide and analyzed with a flow cytometer (FACSCalibur, Becton Dickinson, San Jose, CA, USA). The percentage ± s.d. of cells in each cell-cycle phase was determined by ModFit LT software (Verity Software House, Inc., Topsham, ME, USA). Flow cytometry was also used to analyze cell surface molecule expression on NECs and rTECs, as reported.
RNA isolation and quantitative real-time PCR for IL-3, VEGF, E-selectin, ICAM-1 and mbKitL expression Total RNA was isolated using TRIzol Reagent (Invitrogen, Frederick, MD, USA) from untreated or 48-h treated cells, as indicated, following the manufacturer's instructions. Singlestranded complementary DNA was synthesized from 50 ng of total RNA using a reverse transcription kit. Each complementary DNA generated was amplified by quantitative real-time-PCR in the ABI PRISM 7700 (Applied Biosystems, Foxter Cyto, CA, USA). GAPDH gene was used as standard reference. The relative expression of IL-3, VEGF, mbKitL, E-selectin, and ICAM-1 was calculated by using comparative threshold cycle methods. IL-3 and VEGF mRNA quantification was obtained using specific Taq-Man Gene Expression assay. mbKitL, E-selectin and ICAM-1 mRNA expression was determined using the following primer sequences:
sense (5 0 -CCATTGATGCCTTCAAGGAC-3 0 ) and antisense (5 0 -GGCTGTCTCTTCTTCGAGTA-3 0 ) for mbKitL; sense (5 0 -CAGTGACCATCTACAGCTTTCCGG-3 0 ) and antisense (5 0 -GCTGCTACCACAGTGATGATGACAA-3 0 ) for ICAM-1; sense (5 0 -CCAGTGCTTATTGTCAGC-3 0 ) and antisense (5 0 -CACATTGCAGGCTGGAAT-3 0 ) for E-selectin.
Adhesion assay
Adhesion of EPCs or inflammatory cells to rTECs or mTECs (data not shown) was assayed in static conditions (Biancone et al., 2004) . Briefly, EPCs or inflammatory cells were labelled with the red fluorescent PKH26 (Sigma-Aldrich) vital dye and, after centrifugation at 1400 g for 10 min, were re-suspended in medium free containing 0.25% bovine serum albumin. Cells were then added (at 2 Â 10 5 cells per well) to confluent monolayer of TECs, untreated or treated as indicated, to neutralize IL-3, mbKitL or Akt action. Co-cultures were thus incubated at 37 1C for 4 h and non-adherent cells were removed by washing three times with phosphate-buffered saline. Samples were then fixed with 4% formaldehyde/ phosphate-buffered saline and observed under an epifluorescence microscope. Bound labelled EPCs or inflammatory cells were counted by three different operators in triplicate (10 fields at Â 20 magnification per sample).
Tube-like structure formation assay
To analyze tube-like structure formation 24-well plates were coated with growth factor-reduced Matrigel (BD Biosciences, San Jose, CA, USA). rTECs or mTECs were placed on top of the polymerized matrix, in presence or in absence of the anti-IL-3-neutralizing Ab. Alternatively, TECs depleted of IL-3 or Akt were used. After 6 h, tube-like structure formation was evaluated by three different operators (each experiment was performed in triplicate), counting 10 fields at Â 20 magnification.
In vivo experiments For angiogenesis assay SCID mice (five mice for each experimental group), purchased from Charles River Laboratories International Inc., Wilmington, MA, USA, were injected subcutaneously into the left flank with growth factor-reduced Matrigel containing 2 Â 10 6 rTECs or mTECs, alone or in combination with an anti-IL-3-neutralizing Ab or TECs silenced for IL-3 or for Akt. Seven days later, Matrigel plugs were recovered and fixed in 10% buffered formalin and embedded in paraffin for histological and immunofluorescence analysis. The vessel area and the total Matrigel area were planimetrically assessed from hematoxylin-eosin stained sections as previously described (Dentelli et al., 1999) . Only the structures possessing a patent lumen and containing red blood cells were considered vessels. Angiogenesis was expressed as the percentage±s.d. of the vessel area to the total Matrigel area (% vessel area, Â 10 magnification). Quantification of neoformed vessels was also evaluated by human CD31 staining of vascular TECs. Any stained CD31 þ cell or CD31 þ cell cluster, clearly separated from connective tissue elements, was considered as a single microvessel and counted, according to Weidner et al. (1991) . To study in vivo EPC or inflammatory cell homing to tumor neo-vasculature, rTECs or mTECs (data not shown), in presence or in absence of the anti-mbKitLneutralizing Ab, were added to Matrigel and injected subcutaneously into the left flank of SCID mice (five mice for each experimental group). To evaluate EPC homing, 5 days after Matrigel injection 2 Â 10 6 EPCs were labelled with fluorescent dye carboxyfluorescein diacetate succinimidyl ester (Molecular Probes, Invitrogen) (To¨gel et al., 2005) and injected in the tail vein of the mice. After 2 days mice were killed, and Matrigel plugs were recovered and analyzed by immunohistochemistry. To study inflammatory cell homing, 7 days after TEC implantation into SCID mice Matrigel plugs were recovered and processed for immunohistochemistry. Animal procedures conformed to the Guide for Care and Use of Laboratory Resources (National Institutes of Health publication no. 93-23, revised 1985) .
Immunohistochemistry
Sections from paraffin-embedded blocks of Matrigel plugs were collected onto poly-lysine-coated slides. Endogenous peroxidase activity was blocked with 6% H 2 O 2 for 8 min at room temperature. To detect carboxyfluorescein diacetate succinimidyl ester-labelled EPCs, an anti-fluorescein/Oregon Green polyclonal Ab (dilution 1:1000, Molecular Probes) was applied to slides overnight at 4 1C. To detect inflammatory cells an anti-CD68 polyclonal Ab (dilution 1:1000, DAKO, Glostrup, Denmark) was used. Horseradish peroxidaselabelled anti-rabbit Envision polymer (DAKO) was incubated for 30 min at room temperature. The reaction product was developed using 3,3-diaminobenzidine solution (DAKO). Sections were counterstained with hematoxylin. Omission of the primary Ab or substitution with an unrelated rabbit serum immunoglobulin G served as negative control. The number of positive cells (EPCs/vessel or inflammatory cells per field) was counted in six non-sequential sections by three different operators ( Â 20 magnification). Quantification of neoformed vessels was also evaluated by human CD31 staining of vascular TECs, as above described, and reported as number (mean ± s.d.) of vessels per field ( Â 20 magnification).
Immunofluorescence analysis
Sections from paraffin-embedded blocks of Matrigel plugs were collected onto poly-lysine-coated slides and processed using anti-human CD31-FITC Ab and DAPI (Sigma-Aldrich), as nuclear marker. Human CD31-positive vessels were determined by counting 10 randomly selected fields in three different samples ( Â 20 magnification). Images were acquired with a Zeiss LSM 5 Pascal confocal laser-scanning microscope (Carl Zeiss, Jena, Germany) equipped with a helium/neon laser (543 mm), an argon laser (450-530 mm), and an EC planar Neofluar Â 40/1.3 oil-immersion DIC objective lens. Images were analyzed using Zeiss LSM 5 version 3.2 software.
Xenograft experiments
For in vivo tumor growth 5 Â 10 6 of primary renal carcinoma cells were injected subcutaneously into the left flank of SCID mice (six mice for each experimental group), in presence or in absence (saline) of the anti-IL-3 Ab. Either saline and Ab were injected every 2 days into the tumors for a total of 36 days. Tumor size was measured by using a calliper every 3 days and calculated using the formula: V ¼ 4/3p Â (d/2) 2 Â (D/2) (d stands for minor tumor axis; D stands for major tumor axis). Animals were killed approximately after 4-5 weeks, when tumors reached a volume of B450 mm 3 . Sections from tumors were fixed and processed for histological analysis. Quantification of intra-tumoral vessel density was evaluated as above described. Animal procedures conformed to the Guide for Care and Use of Laboratory Resources.
Statistical analysis
All in vitro and in vivo results are representative of at least three independent experiments, performed in triplicate. Densitometric analysis using a Bio-Rad GS 250 molecular imager (Bio-Rad Laboratories, Hercules, CA, USA) was used to calculate the differences in the fold induction of protein levels, normalized to b-actin content (*Po0.05, statistically significant between experimental and control values) and each western blot panel and relative densitometric histogram reported in the figures were representative of the results obtained in triplicate. Significance of differences between experimental and control values (*Po0.05) for both in vitro and in vivo experiments was calculated using analysis of variance with Newman-Keuls multi-comparison test, and reported in detail in each figure legend.
